Table 3.

Daily Trial – Demographic and clinical characteristics for subjects with 12-month SBP declines of at least 30 mmHg. Changes (Δ) are calculated as F10–12 minus baseline (BL).

Pat #	Arm	Pre-HD SBP [mm Hg]		# Antihyper- tensive drugs		Age (yr)	Vintage (yr)	IDWG [kg]		Pre-HD Weight [kg]
		BL	Δ	BL	Δ			BL	Δ	BL	Δ
1	6× weekly	191	−63.9	3	0	45.8	3.2	2.4	−0.94	73.5	2.0
2	3× weekly	196	−49.8	1	1	53	4.9	5.2	−1.76	103.4	−9.1
3	6× weekly	177	−49.6	4	−4	55.2	6.7	4.4	−1.86	95.9	2.3
4	6× weekly	160	−42.8	4	0	41.9	6.0	5.2	−1.97	79.3	−2.2
5	6× weekly	155	−41.4	1	−1	34.3	8.1	4.4	−3.77	76.2	−8.8
6	6× weekly	171	−40.4	1	0	79.6	1.7	3.0	−1.99	70.1	1.6
7	6× weekly	164	−37.0	3	−2	41.5	7.2	3.6	−1.31	75.7	2.5
8	6× weekly	157	−34.6	4	−2	35.6	4.0	1.4	−0.82	103.9	2.5
9	6× weekly	130	−33.7	2	−2	59.7	6.6	2.2	−0.76	45.1	−0.1
10	6× weekly	190	−32.9	0	0	64.2	3.8	3.2	−0.81	96.1	−2.6
11	6× weekly	168	−32.5	2	−1	58.8	1.0	3.4	−1.20	79.2	1.5
12	3× weekly	160	−30.9	0	1	37	3.0	4.8	−0.05	101.5	−2.3
13	6× weekly	159	−30.7	3	−2	42.4	5.2	4.2	−1.71	106.9	−0.9
14	6× weekly	152	−30.7	0	0	53.9	3.6	1.8	0.79	71.1	8.2
15	6× weekly	148	−30.2	6	−4	51.1	19.3	2.4	−0.77	92.9	−4.3
16	6× weekly	146	−30.1	1	−1	77.4	0.6	2.8	−1.46	75.6	−2.6
Remainder 3× weekly 1		145 [17.1]	1.6 [15.3]	2.2 [1.4]	−0.3 [1.1]	52.2 [14.1]	5.1 [5.3]	3.1 [0.91]	−0.02 [0.76]	81.5 [20.9]	0.37 [3.21]
Remainder 6× weekly 1		145 [17.8]	−5.3 [15.0]	2.2 [1.6]	−0.7 [1.6]	48.3 [13.5]	6.4 [6.9]	3.1 [0.99]	−1.01 [0.81]	80.7 [21.6]	0.14 [4.00]

¹Statistics for subjects with values at both baseline and F10–12.